- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/735 - Fc receptors
Patent holdings for IPC class C07K 14/735
Total number of patents in this class: 673
10-year publication summary
|
43
|
53
|
74
|
62
|
66
|
74
|
63
|
77
|
59
|
29
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Immunitybio, Inc. | 514 |
50 |
| Regeneron Pharmaceuticals, Inc. | 4810 |
32 |
| FATE Therapeutics, Inc. | 237 |
24 |
| Tosoh Corporation | 1432 |
18 |
| Cellectis | 416 |
17 |
| The Trustees of the University of Pennsylvania | 4437 |
15 |
| NantKwest, Inc. | 48 |
13 |
| Xencor, Inc. | 409 |
11 |
| GI Innovation, Inc. | 62 |
11 |
| Novartis AG | 10169 |
10 |
| Autolus Limited | 272 |
10 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3015 |
10 |
| Zymeworks Inc. | 258 |
9 |
| Hoffmann-La Roche Inc. | 3841 |
8 |
| Chugai Seiyaku Kabushiki Kaisha | 1426 |
8 |
| Regents of the University of Minnesota | 2809 |
8 |
| SuppreMol GmbH | 24 |
7 |
| F. Hoffmann-La Roche AG | 7798 |
6 |
| 1Globe Biomedical Co., Ltd. | 31 |
6 |
| Ramot at Tel-Aviv University Ltd. | 1556 |
6 |
| Other owners | 394 |